Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12708273 | 0.90 | ACHE (0.71) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9018822 | 0.90 | CA4 (0.59) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4270701 | 0.89 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11021872 | 0.89 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17052772 | 0.88 | TDP1 (0.73) | CA1CA2CA7CA9CA12 | |
| SCHEMBL26193671 | 0.88 | LTA4H (0.64) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10948006 | 0.87 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19888533 | 0.82 | ALDH1A1 (0.76) | CA1CA2CA7CA9CA12 | |
| SCHEMBL12589778 | 0.82 | APP (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL482369 | 0.82 | CA1 (0.65) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163101-A1 | METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE | Research & Business Foundation Sungkyunkwan University (KR) | 2025-05-22 | — | — | US | claimed |
| EP-4488290-A1 | METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE | ABTIS Co., Ltd. (KR) | 2025-01-08 | — | — | EP | claimed |
| WO-2024257830-A1 | METHOD FOR PRODUCING AZULENE AND RELATED COMPOUNDS | アルプス薬品工業株式会社 | 2024-12-19 | — | — | WO | claimed |
| CN-118026909-B | Preparation method of 3, 3-diaryl indolenine series compounds | 江西师范大学 | 2024-06-21 | — | — | CN | claimed |
| CN-118026909-A | Preparation method of 3, 3-diaryl indolenine series compounds | 江西师范大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117945964-A | Synthesis method of aryl alkyl asymmetric thioether | 中国人民解放军军事科学院防化研究院 | 2024-04-30 | — | — | CN | claimed |
| WO-2023167564-A1 | METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE | 앱티스 주식회사 | 2023-09-07 | — | — | WO | claimed |
| CN-116704872-A | Preparation method of surface-enhanced Raman label | 南京工业大学 | 2023-09-05 | — | — | CN | claimed |
| CN-115197179-B | Method for preparing thioether and disulfide through C-S bond double decomposition reaction without participation of transition metal | 常州大学 | 2023-08-22 | — | — | CN | claimed |
| CN-111052485-B | Non-aqueous electrolyte for lithium secondary battery and lithium secondary battery comprising the same | 株式会社LG新能源 | 2023-04-14 | — | — | CN | claimed |
| US-20150083466-A1 | Method For The Functionalisation Of Metal Nanowires And The Production Of Electrodes | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-03-26 | — | — | US | claimed |
| US-20130330607-A1 | ELECTROLYTIC SOLUTION AND LITHIUM-ION SECONDARY BATTERY | KABUSHIKI KAISHA TOYOTA JIDOSHOKKI (JP) | 2013-12-12 | — | — | US | claimed |
| EP-1304758-B1 | NON-AQUEOUS ELECTROLYTE AND NON-AQUEOUS ELECTROLYTE SECONDARY CELL | PANASONIC CORP (JP) | 2009-05-27 | — | — | EP | claimed |
| EP-1199766-B1 | Non-aqueous secondary battery having enhanced discharge capacity retention | UBE INDUSTRIES (JP) | 2008-05-28 | — | — | EP | claimed |
| US-7132199-B2 | Non-aqueous electrolyte and non-aqueous electrolyte secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2006-11-07 | — | — | US | claimed |
| US-6866966-B2 | Efficiency | UBE INDUSTRIES, LTD. (JP) | 2005-03-15 | — | — | US | claimed |
| US-20040091786-A1 | Non-aqueous electrolyte and non-aqueous electrolyte secondary cell | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1304758-A1 | NON-AQUEOUS ELECTROLYTE AND NON-AQUEOUS ELECTROLYTE SECONDARY CELL | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | claimed |
| US-20020122988-A1 | Efficiency | UBE INDUSTRIES, LTD. (JP) | 2002-09-05 | — | — | US | claimed |
| EP-1199766-A2 | Non-aqueous secondary battery having enhanced discharge capacity retention | Ube Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163101-A1 | METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE | TST, DHFR, FCGRT | CA1 955/4885CA2 1903/4885CA7 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.